Investor Information

Aisa is currently raising a Series A round in the amount of $20M to complete development of AISA-021 for the treatment of Raynaud’s in patients with Systemic Sclerosis. The company has until this point been financed with seed and angel investments. For information or to obtain a copy of financing documents please email us at ir@aisapharma.com.